References considered in our research

References are given in alphabetic order .

  1. Adachi, Y.; Suzuki, H.; Schinkel, A. H.; Sugiyama, Y. Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen. Mol. Pharmacol. 2005, 67, 923-928.
     
  2. Alekshun, M. N.; Levy, S. B. Molecular mechanisms of antibacterial multidrug resistance. Cell 2007, 128, 1037-1050.
     
  3. Aminetzach, Y. T.; Macpherson, J. M.; Petrov, D. A. Pesticide resistance via transposition-mediated adaptive gene truncation in Drosophila. Science 2005, 309, 764-767.
     
  4. Andreadis, C.; Gimotty, P. A.; Wahl, P.; Hammond, R.; Houldsworth, J.; Schuster, S. J.; Rebbeck, T. R. Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma. Blood 2007, 109, 3409-3416.
     
  5. Apperley, J. F. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007, 8, 1018-1029.
     
  6. Assaraf, Y. G. Molecular basis of antifolate resistance. Cancer Metastasis Rev. 2007, 26, 153-81.
     
  7. Bacic, M.; Parker, A. C.; Stagg, J.; Whitley, H. P.; Wells, W. G.; Jacob, L. A.; Smith, C.J. Genetic and structural analysis of the Bacteroides conjugative transposon CTn341. J. Bacteriol. 2005, 187, 2858-2869.
     
  8. Badagnani, I.; Castro, R. A.; Taylor, T. R.; Brett, C. M.; Huang, C. C.; Stryke, D.; Kawamoto, M.; Johns, S. J.; Ferrin, T. E.; Carlson, E. J.; Burchard, E. G.; Giacomini, K. M. Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J. Pharmacol. Exp. Ther. 2006, 318, 521-529.
     
  9. Baer, B. R.; Rettie, A. E. CYP4B1: an enigmatic P450 at the interface between xenobiotic and endobiotic metabolism. Drug Metab. Rev. 2006, 38, 451-457.
     
  10. Bai, J.; Lai, L.; Yeo, H. C.; Goh, B. C.; Tan, T. M. Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. Int. J. Biochem. Cell. Biol. 2004, 36, 247-257.
     
  11. Baron, J. M.; Zwadlo-Klarwasser, G.; Jugert, F.; Hamann, W.; Rubben, A.; Mukhtar, H.; Merk, H. F. Cytochrome P450 1B1: a major P450 isoenzyme in human blood monocytes and macrophage subsets. Biochem. Pharmacol. 1998, 56, 1105-1110.
     
  12. Benderra, Z.; Trussardi, A.; Morjani, H.; Villa, A. M.; Doglia, S. M.; Manfait, M. Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein. Eur. J. Cancer. 2000, 36, 428-434.
     
  13. Bernauer, U.; Garritsen, H.; Heinrich-Hirsch, B.; Gundert-Remy, U. Immunochemical analysis of cytochrome P450 variability in human leukapheresed samples and its consequences for the risk assessment process. Regul. Toxicol. Pharmacol. 2003, 37, 318-327.
     
  14. Bièche, I.; Narjoz, C.; Asselah, T.; Vacher, S.; Marcellin, P.; Lidereau, R.; Beaune, P.; de Waziers, I. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet. Genomics. 2007, 17, 731-742.
     
  15. Bogush, T. A.; Ravcheeva, A. B.; Bogush, E. A.; Konukhova, A. V.; Kuz'mina, K. E.; Baryshnikov, A. Y.; Davydov, M. I. Extracellular concentration of anticancer drugs that regulates their intracellular distribution and binding to DNA in cells with multidrug resistant phenotype. Dokl. Biochem. Biophys. 2006, 410, 273-277.
     
  16. Bort, R.; Macé, K.; Boobis, A.; Gómez-Lechón, M. J.; Pfeifer, A.; Castell J. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem. Pharmacol. 1999, 58, 787-796.
     
  17. Bournique, B.; Lemarié, A. Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme. Drug Metab. Dispos. 2002, 30, 1149-1152.
     
  18. Bowen, D. T.; Frew, M. E.; Rollinson, S.; Roddam, P. L.; Dring, A.; Smith, M. T.; Langabeer, S. E.; Morgan, G. J. CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated with FLT3 internal tandem duplication. Blood 2003, 101, 2770-2774.
     
  19. Bradshaw, T. D.; Stone, E. L.; Trapani, V.; Leong, C. O.; Matthews, C. S.; te Poele, R.; Stevens, M. F. Mechanisms of acquired resistance to 2-(4-Amino-3-methylphenyl)benzothiazole in breast cancer cell lines. Breast Cancer Res. Treat. 2008, 110, 57-68.
     
  20. Brantley, E.; Trapani, V.; Alley, M. C.; Hose, C. D.; Bradshaw, T. D.; Stevens, M. F.; Sausville, E. A.; Stinson, S. F. Fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells. Drug Metab. Dispos. 2004, 32, 1392-1401.
     
  21. Burt, R. K.; Thorgeirsson, S. S. Coinduction of MDR 1 multidrug resistance and cytochrome P 450 genes in rat liver by xenobiotics. Journal of the National Cancer Institute 1988, 80, 1383 1386.
     
  22. Calin, G. A.; Croce, C. M. Investigation of MicroRNA Alterations in Leukemias and Lymphomas. Methods Enzymol. 2007, 427, 191-213.
     
  23. Catania, F.; Kauer, M. O.; Daborn, P. J.; Yen, J. L.; Ffrench-Constant, R.H.; Schlotterer, C. Worldwide survey of an Accord insertion and its association with DDT resistance in Drosophila melanogaster. Mol. Ecol. 2004, 13, 2491-2504.
     
  24. Chen, C. S.; Jounaidi, Y.; Su, T.; Waxman, D. J. Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model. Cancer Gene Ther. 2007, 14, 935-944.
     
  25. Chen, S.; Li, X. Transposable elements are enriched within or in close proximity to xenobiotic-metabolizing cytochrome P450 genes. BMC Evol. Biol. 2007, 7, 46-58.
     
  26. Cheng, X.; Maher, J.; Dieter, M. Z.; Klaassen, C. D. Regulation of mouse organic anion-transporting polypeptides (Oatps) in liver by prototypical microsomal enzyme inducers that activate distinct transcription factor pathways. Drug Metab. Dispos. 2005, 33, 1276-1282.
     
  27. Chloupková, M.; Pickert, A.; Lee, J.Y.; Souza, S.; Trinh, Y.T.; Connelly, S.M.; Dumont. M.E.; Dean, M.; Urbatsch, I.L. Expression of 25 human ABC transporters in the yeast Pichia pastoris and characterization of the purified ABCC3 ATPase activity. Biochemistry 2007, 46, 7992-8003.
     
  28. Chua, M. S.; Kashiyama, E.; Bradshaw, T. D.; Stinson, S. F.; Brantley, E.; Sausville, E. A.; Stevens, M. F. Role of Cyp1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells. Cancer Res. 2000, 60, 5196-5203.
     
  29. Chung, H.; Bogwitz, M. R.; McCart, C.; Andrianopoulos, A.; Ffrench-Constant, R.H.; Batterham, P.; Daborn, P.J. Cis-regulatory elements in the Accord retrotransposon result in tissue-specific expression of the Drosophila melanogaster insecticide resistance gene Cyp6g1. Genetics 2007, 175, 1071-1077.
     
  30. Colombo, S.; Telenti, A.; Buclin, T.; Furrer, H.; Lee, B. L.; Biollaz, J.; Decosterd, L. A.; Swiss HIV Cohort Study. Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients? Ther. Drug Monit. 2006, 28, 332-338.
     
  31. Crossman, L. C.; Druker, B. J.; Deininger, M. W.; Pirmohamed, M.; Wang, L.; Clark, R. E. hOCT 1 and resistance to imatinib. Blood 2005, 106, 1133-1134.
     
  32. Csoka K, Larsson R, Tholander B, Gerdin E, de la Torre M, Nygren P.Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Gynecol Oncol. 1994;54:163-70.
     
  33. Cui, Y.; König, J.; Keppler, D. Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol. Pharmacol. 2001, 60, 934-943.
     
  34. Cummings, J.; Boyd, G.; Ethell, B. T.; Macpherson, J. S.; Burchell, B.; Smyth, J. F.; Jodrell, D. I. Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation. Biochem. Pharmacol. 2002, 63, 607-613.
     
  35. Cummings, J.; Ethell, B. T.; Jardine, L.; Boyd, G.; Macpherson, J. S.; Burchell, B.; Smyth, J. F.; Jodrell, D. I. Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives. Cancer Res. 2003, 63, 8443-8450.
     
  36. Cummings, J.; Ethell, B. T.; Jardine, L.; Burchell, B. Glucuronidation of SN-38 and NU/ICRF 505 in human colon cancer and adjacent normal colon. Anticancer Res. 2006, 26, 2189-2196.
     
  37. Cummings, J.; Zelcer, N.; Allen, J. D.; Yao, D.; Boyd, G.; Maliepaard, M.; Friedberg, T. H.; Smyth, J. F.; Jodrell, D. I. Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins. Biochem. Pharmacol. 2004, 67, 31-39.
     
  38. Daborn, P. J.; Yen, J. L.; Bogwitz, M. R.; Le Goff, G.; Feil, E.; Jeffers, S.; Tijet, N.; Perry, T.; Heckel, D.; Batterham, P.; Feyereisen, R.; Wilson, T. G.; Ffrench-Constant, R. H. A single P450 allele associated with insecticide resistance in Drosophila. Science 2002, 297, 2253-2256.
     
  39. Decleves, X.; Bihorel, S.; Debray, M.; Yousif, S.; Camenisch, G.; Scherrmann, J. M. ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells. Pharmacological Research 2008, 57, 214-222.
     
  40. DeMichele, A.; Aplenc, R.; Botbyl, J.; Colligan, T.; Wray, L.; Klein-Cabral, M.; Foulkes, A.; Gimotty, P.; Glick, J.; Weber, B.; Stadtmauer E.; Rebbeck T. R. Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort. J. Clin. Oncol. 2005, 23, 5552-5559.
     
  41. Dhaini, H. R.; Thomas, D. G.; Giordano, T. J.; Johnson, T. D.; Biermann, J. S.; Leu, K.; Hollenberg, P. F.; Baker, L. H. Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. J. Clin. Oncol. 2003, 21, 2481-2485.
     
  42. Doherty MM and Michael M. Tumoral Drug Metabolism : Perspectives and Therapeutic Implications. Curr.Drug Metab (2003), 4, 131-149
     
  43. Donato, N. J.; Wu, J. Y.; Stapley, J.; Lin, H.; Arlinghaus, R.; Aggarwal, B. B.; Shishodia, S.; Albitar, M.; Hayes, K.; Kantarjian, H.; Talpaz, M. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. 2004, 64, 672-677.
     
  44. Downie, D.; McFadyen, M. C.; Rooney, P. H.; Cruickshank, M. E.; Parkin, D. E.; Miller, I. D.; Telfer, C.; Melvin, W. T.; Murray, G. I. Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin. Cancer Res. 2005, 11, 7369-7375.
     
  45. Duensing, S.; Dallmann, I.; Grosse, J.; Buer, J.; Lopez Hänninen, E.; Deckert, M.; Störkel, S.; Kirchner, H.; Poliwoda, H.; Atzpodien, J. Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patients. Oncology 1994, 51, 309-313.
     
  46. Duesberg, P.; Li, R.; Sachs, R.; Fabarius, A.; Upender, M. B.; Hehlmann, R. Cancer drug resistance, the central role of the karyotype. Drug Resist. Updat. 2007, 10, 51-58.
     
  47. Efferth, T.; Volm, M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol. Ther. 2005, 107, 155-176.
     
  48. Ehrlich, M. Cancer-linked DNA hypomethylation and its relationship to hypermethylation. Curr. Top. Microbiol. Immunol. 2006, 310, 251-274.
     
  49. Fojo, T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist.Updat. 2007, 10, 59-67.
     
  50. Ford, J.; Cornforth, D.; Hoggard, P. G.; Cuthbertson, Z.; Meaden, E. R.; Williams, I.; Johnson, M.; Daniels, E.; Hsyu, P.; Back, D. J.; Khoo, S. H. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression. Antivir. Ther. 2004, 9, 77-84.
     
  51. Fotoohi, A. K.; Albertioni, F. Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells. Leuk. Lymphoma. 2008, 49, 410-426.
     
  52. Friedenberg, W. R.; Rue, M.; Blood, E. A.; Dalton, W. S.; Shustik, C.; Larson, R. A.; Sonneveld, P.; Greipp, P. R. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer 2006, 106, 830-838.
     
  53. Furukawa, M.; Nishimura, M.; Ogino, D.; Chiba, R.; Ikai, I.; Ueda, N.; Naito, S.; Kuribayashi, S.; Moustafa, M. A.; Uchida, T.; Sawada, H.; Kamataki, T.; Funae, Y.; Fukumoto, M. Cytochrome p450 gene expression levels in peripheral blood mononuclear cells in comparison with the liver. Cancer Sci. 2004, 95, 520-529.
     
  54. Gillet, J. P.; Efferth, T.; Remacle, J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim. Biophys. Acta. 2007, 1775, 237-262.
     
  55. Goetz, M. P.; Rae, J. M.; Suman, V. J.; Safgren, S. L.; Ames, M. M.; Visscher, D. W.; Reynolds, C.; Couch, F. J.; Lingle, W. L.; Flockhart, D. A.; Desta, Z.; Perez, E. A.; Ingle, J. N. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 2005, 23, 9312-9318.
     
  56. Goodier, J. L.; Kazazian, H.H. Jr. Retrotransposons revisited: the restraint and rehabilitation of parasites. Cell 2008, 135, 23-35.
     
  57. Groninger, E.; Koopmans, P.; Kamps, W.; de Graaf, S.; Uges, D. An automated HPLC method to determine intracellular vincristine concentrations in mononuclear cells of children with acute lymphoblastic leukemia. Ther. Drug Monit. 2003, 25, 441-446.
     
  58. Guns, E. S.; Bullock, P. L.; Reimer, M. L.; Dixon, R.; Bally, M.; Mayer, L. D. Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes. Eur. J. Drug Metab. Pharmacokinet. 2001, 26, 273-282.
     
  59. Gupta, V. Metallo beta lactamases in Pseudomonas aeruginosa and Acinetobacter species. Expert Opin. Investig. Drugs. 2008, 17, 131-143.
     
  60. Haber, M.; Smith, J.; Bordow, S. B.; Flemming, C.; Cohn, S. L.; London, W. B.; Marshall, G. M.; Norris, M. D. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J. Clin. Oncol. 2006, 24, 1546-1553.
     
  61. Hammond, S. M. RNAi, microRNAs, and human disease. Cancer Chemother. Pharmacol. 2006, 58, 63-68.
     
  62. Haouala A, Zanolari B, Rochat B, Montemurro M, Zaman K, Duchosal MA, Ris HB, Leyvraz S, Widmer N, Decosterd LA. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:1982-1996.
     
  63. Hashizume, T.; Imaoka, S.; Mise, M.; Terauchi, Y.; Fujii, T.; Miyazaki, H.; Kamataki, T.; Funae, Y. Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J. Pharmacol. Exp. Ther. 2002, 300, 298-304.
     
  64. Hess, G.; Meyer, R. G.; Schuch, B.; Bechthold, K.; El-Kholy, I.; Huber C. Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: A 5-year follow up. Am. J. Hematol. 2008, 83, 178-184.
     
  65. Hochhaus, A.; Kreil, S.; Corbin, A. S.; La Rosée, P.; Müller, M. C.; Lahaye, T.; Hanfstein, B.; Schoch, C.; Cross, N. C.; Berger, U.; Gschaidmeier, H.; Druker, B. J.; Hehlmann, R. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002, 16, 2190-2196.
     
  66. Hofbauer GF, Hatta N, Daigle I, Hemmi S, Spanaus Schlapbach K, Willers J, Burg G, Simon HU, Dummer R. Fas ligand reduces viability in primary melanoma short-term cell cultures more than in metastatic melanoma short-term cell cultures. Dermatology. 2005;211:318-324.
     
  67. Hu, M.; Krausz, K.; Chen, J.; Ge, X.; Li, J.; Gelboin, H. L.; Gonzalez, F. J. Identification of CYP1A2 as the main isoform for the phase I hydroxylated metabolism of genistein and a prodrug converting enzyme of methylated isoflavones. Drug Metab. Dispos. 2003, 31, 924-931.
     
  68. Hu, R.; Shen, G.; Yerramilli, U. R.; Lin, W.; Xu, C.; Nair, S.; Kong, A. N. In vivo pharmacokinetics, activation of MAPK signaling and induction of phase II/III drug metabolizing enzymes/transporters by cancer chemopreventive compound BHA in the mice. Arch. Pharm. Res. 2006, 29, 911-920.
     
  69. Huang, L.; Wring, S. A.; Woolley, J. L.; Brouwer, K. R.; Serabjit-Singh, C.; Polli, J. W. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab. Dispos. 2001, 29, 754-760.
     
  70. Huang, Y. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev. 2007, 26, 183-201.
     
  71. Huang, Y.; Anderle, P.; Bussey, K. J.; Barbacioru, C.; Shankavaram, U.; Dai, Z.; Reinhold, W. C.; Papp, A.; Weinstein, J. N.; Sadee, W. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res. 2004, 64, 4294-4301.
     
  72. Huang, Y.; Sadee, W. Membrane transporters and channels in chemoresistance and sensitivity of tumor cells. Cancer Lett. 2005, 239, 168-182.
     
  73. Huff, L. M.; Lee, J. S.; Robey, R. W.; Fojo, T. Characterization of gene rearrangements leading to activation of MDR-1. J. Biol. Chem. 2006, 281, 36501-36509.
     
  74. Imaoka, S.; Yoneda, Y.; Sugimoto, T.; Hiroi, T.; Yamamoto, K.; Nakatani, T.; Funae, Y. CYP4B1 is a possible risk factor for bladder cancer in humans. Biochem. Biophys. Res. Commun. 2000, 277, 776-780.
     
  75. Information available at the Food and Drug Administration web site : http://www.fda.gov/cder/approval/index.htm
     
  76. Innocenti F, Iyer L, Ratain MJ. Pharmacogenetics: a tool for individualizing antineoplastic therapy. Clin Pharmacokinet 2000; 39: 315-25
     
  77. Innocenti, F.; Iyer, L.; Ratain, M. J. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab. Dispos. 2001, 29, 596-600.
     
  78. Ishii, Y.; Takeda, S.; Yamada, H.; Oguri, K. Functional protein-protein interaction of drug metabolizing enzymes. Front. Biosci. 2005, 10, 887-895.
     
  79. Ishikawa, T.; Tamura, A.; Saito, H.; Wakabayashi, K.; Nakagawa, H. Pharmacogenomics of the human ABC transporter ABCG2: from functional evaluation to drug molecular design. Naturwissenschaften 2005, 92, 451-463.
     
  80. Ishizuka, H.; Konno, K.; Naganuma, H.; Nishimura, K.; Kouzuki, H.; Suzuki, H.; Stieger, B.; Meier, P. J.; Sugiyama, Y. Transport of temocaprilat into rat hepatocytes: role of organic anion transporting polypeptide. J. Pharmacol. Exp. Ther. 1998, 287, 37-42.
     
  81. Jellen-Ritter, A. S.; Kern, W. V. Enhanced expression of the multidrug efflux pumps AcrAB and AcrEF associated with insertion element transposition in Escherichia coli mutants Selected with a fluoroquinolone. Antimicrob. Agents Chemother. 2001, 45, 1467-1472.
     
  82. Jensen, S. A.; Vainer, B.; Sorensen, J. B. The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil. Int. J. Cancer. 2007, 120, 694-701.
     
  83. Jeong, E. J.; Liu, X.; Jia, X.; Chen, J.; Hu, M. Coupling of conjugating enzymes and efflux transporters: impact on bioavailability and drug interactions. Curr. Drug Metab. 2005, 6, 455-468.
     
  84. Jiang, J. G.; Chen, C. L.; Card, J. W.; Yang, S.; Chen, J. X.; Fu, X. N.; Ning, Y. G.; Xiao, X.; Zeldin, D. C.; Wang, D.W. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res. 2005, 65, 4707-4715.
     
  85. Jiang JG, Fu XN, Chen CL, Wang DW. Expression of cytochrome P450 arachidonic acid epoxygenase 2J2 in human tumor tissues and cell lines. Chin J Cancer. 2009;28:93-6.
     
  86. Jonsson E, Dhar S, Jonsson B, Nygren P, Graf W, Larsson R. Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines. Eur J Cancer. 2000;36:2120-7.
     
  87. Jounaidi, Y.; Chen, C. S.; Veal, G. J.; Waxman, D. J. Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11. Mol. Cancer Ther. 2006, 5, 541-555.
     
  88. Kalsotra, A.; Turman, C. M.; Kikuta, Y.; Strobel, H. W. Expression and characterization of human cytochrome P450 4F11: Putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol. Appl. Pharmacol. 2004, 199, 295-304.
     
  89. Kamath, A. V.; Wang, J.; Lee, F. Y.; Marathe, P. H. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother. Pharmacol. 2008, 61, 365-376.
     
  90. Karlgren, M.; Gomez, A.; Stark, K.; Svärd, J.; Rodriguez-Antona, C.; Oliw, E.; Bernal, M. L.; Ramón y Cajal, S.; Johansson, I.; Ingelman-Sundberg, M. Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem. Biophys. Res. Commun. 2006, 341, 451-458.
     
  91. Karlgren, M.; Ingelman-Sundberg, M. Tumour-specific expression of CYP2W1: its potential as a drug target in cancer therapy. Expert Opin. Ther. Targets. 2007, 11, 61-67.
     
  92. Karlgren, M.; Miura, S.; Ingelman-Sundberg, M. Novel extrahepatic cytochrome P450s. Toxicol. Appl. Pharmacol. 2005, 207, 57-61.
     
  93. Katragadda, S.; Budda, B.; Anand, B. S.; Mitra, A. K. Role of efflux pumps and metabolising enzymes in drug delivery. Expert. Opin. Drug Deliv. 2005, 2, 683-705.
     
  94. Kawasaki, Y.; Kato, Y.; Sai, Y.; Tsuji, A. Functional characterization of human organic cation transporter OCTN1 single nucleotide polymorphisms in the Japanese population. J. Pharm. Sci. 2004, 93, 2920-2926.
     
  95. Kelner, M. J.; McMorris, T. C.; Montoya, M. A.; Estes, L.; Rutherford, M.; Samson, K. M.; Taetle, R. Characterization of cellular accumulation and toxicity of illudin S in sensitive and nonsensitive tumor cells. Cancer Chemother. Pharmacol. 1997, 40, 65-71.
     
  96. Keppler, D. Export pumps for glutathione S-conjugates. Free Radic. Biol. Med. 1999, 27, 985-91.
     
  97. Keppler, D.; König, J. Hepatic secretion of conjugated drugs and endogenous substances. Semin. Liver Dis. 2000, 20, 265-272.
     
  98. Kim, D. H.; Lee, N. Y.; Sung, W. J.; Baek, J. H.; Kim, J. G.; Sohn, S. K.; Suh, J. S.; Lee, K. S.; Lee, K. B. Multidrug resistance as a potential prognostic indicator in acute myeloid leukemia with normal karyotypes. Acta Haematol. 2005, 114, 78-83.
     
  99. Kim, R. B.; Wandel, C.; Leake, B.; Cvetkovic, M.; Fromm, M. F.; Dempsey, P. J.; Roden, M. M.; Belas, F.; Chaudhary, A. K.; Roden, D. M.; Wood, A. J.; Wilkinson, G. R. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. 1999, 16, 408-414.
     
  100. Kimura, N.; Okuda, M.; Inui, K. Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm. Res. 2005, 22, 255-259.
     
  101. Kivisto KT, Kroemer HK. Use of probe drugs as predictors of drug metabolism in humans. Journal of Clinical Pharmacology 1997; 37: 40S 48S
     
  102. Klaassen, C. D.; Slitt, A.L. Regulation of hepatic transporters by xenobiotic receptors. Curr. Drug Metab. 2005, 6, 309-328.
     
  103. Klein, R.; Ruttkowski, B.; Schwab, S.; Peterbauer, T.; Salmons, B.; Günzburg, W. H.; Hohenadl, C. Mouse mammary tumor virus promoter-containing retroviral promoter conversion vectors for gene-directed enzyme prodrug therapy are functional in vitro and in vivo. J. Biomed. Biotechnol. 2008, 2008, 683505-683515.
     
  104. Kohle, C.; Bock, K. W. Coordinate regulation of Phase I and II xenobiotic metabolisms by the Ah receptor and Nrf2. Biochem. Pharmacol. 2007, 73, 1853-1862.
     
  105. Korfmacher W, Using mass spectrometry for analyzing Drug Metabolism. 2004; CRC Press Publisher, 440 pages
     
  106. Kourti, M.; Vavatsi, N.; Gombakis, N.; Sidi, V.; Tzimagiorgis, G.; Papageorgiou, T.; Koliouskas, D.; Athanassiadou, F. Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia. Int. J. Hematol. 2007, 86, 166-173.
     
  107. Krajinovic, M.; Labuda, D.; Mathonnet, G.; Labuda, M.; Moghrabi, A.; Champagne, J.; Sinnett, D. Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin. Cancer Res. 2002, 8, 802-810.
     
  108. Kumar, G. N.; Walle, U. K.; Walle, T. Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation. J. Pharmacol. Exp. Ther. 1994, 268, 1160-1165.
     
  109. Kumarakulasingham, M.; Rooney, P. H.; Dundas, S. R.; Telfer, C.; Melvin, W. T.; Curran, S.; Murray, G. I. Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis. Clin. Cancer Res. 2005, 11, 3758-3765.
     
  110. Kwon, Y.; Kamath, A. V.; Morris, M. E. Inhibitors of P-glycoprotein-mediated daunomycin transport in rat liver canalicular membrane vesicles. J. Pharm. Sci. 1996, 85, 935-939.
     
  111. Lange, T.; Park, B.; Willis, S. G.; Deininger, M. W. BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy? Cell Cycle 2005, 4, 1761-1766.
     
  112. Lasch, P.; Boese, M.; Pacifico, A.; Diem, M. FT-IR spectroscopic investigations of single cells on the subcellular level. Vibrational Spectroscopy 2002, 28, 147-157.
     
  113. Leslie, E. M.; Ito, K.; Upadhyaya, P.; Hecht, S. S.; Deeley, R. G.; Cole, S. P. Transport of the beta -O-glucuronide conjugate of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by the multidrug resistance protein 1 (MRP1). Requirement for glutathione or a non-sulfur-containing analog. J. Biol. Chem. 2001, 276, 27846-27854.
     
  114. Leung, Y. K.; Lau, K. M.; Mobley, J.; Jiang, Z.; Ho, S. M. Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis. Cancer Res. 2005, 65, 3726-3734.
     
  115. Li, J.; Zhao, M.; He, P.; Hidalgo, M.; Baker, S. D. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin. Cancer Res. 2007, 13, 3731-3737.
     
  116. Li, X.; Schuler, M. A.; Berenbaum, M. R. Molecular mechanisms of metabolic resistance to synthetic and natural xenobiotics. Annu. Rev. Entomol. 2007, 52, 231-253.
     
  117. Liu, K. H.; Kim, M. G.; Lee, D. J.; Yoon, Y. J.; Kim, M. J.; Shon, J. H.; Choi, C. S.; Choi, Y. K.; Desta, Z.; Shin, J. G. Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab. Dispos. 2006, 34, 1793-1797.
     
  118. Longley, D. B.; Allen, W. L.; Johnston, P. G. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim. Biophys. Acta. 2006, 1766, 184-196.
     
  119. Lubelski, J.; Konings, W. N.; Driessen, A. J. Distribution and physiology of ABC-type transporters contributing to multidrug resistance in bacteria. Microbiol. Mol. Biol. Rev. 2007, 71, 463-476.
     
  120. Ma, J.; Waxman, D. J. Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment. Mol. Cancer Ther. 2007, 6, 2879-2890.
     
  121. Mandal, P.K.; Kazazian, H.H. Jr. SnapShot: Vertebrate transposons. Cell 2008, 135, 192-192.
     
  122. Marsano, R. M.; Caizzi, R.; Moschetti, R.; Junakovic, N. Evidence for a functional interaction between the Bari1 transposable element and the cytochrome P450 cyp12a4 gene in Drosophila melanogaster. Gene 2005, 357, 122-128.
     
  123. Marsh, S.; Somlo, G.; Li, X.; Frankel, P.; King, C. R.; Shannon, W. D.; McLeod, H. L.; Synold, T. W. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J. 2007, 7, 362-365.
     
  124. Marull, M.; Rochat, B. Fragmentation Study of Imatinib and Characterization of New Imatinib Metabolites by Liquid Chromatography – Triple Quadrupole and Linear Ion Trap Mass Spectrometers. J. Mass Spectrom. 2006, 41, 390-404.
     
  125. Matsumoto, S.; Hirama, T.; Matsubara, T.; Nagata, K.; Yamazoe, Y. Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metab. Dispos. 2002, 30, 1240-1245.
     
  126. McFadyen, M. C.; Murray, G. I. Cytochrome P450 1B1: a novel anticancer therapeutic target. Future Oncol. 2005, 1, 259-263.
     
  127. McFadyen, M.C.; McLeod, H.L.; Jackson, F.C.; Melvin, W.T.; Doehmer, J.; Murray, G.I. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem. Pharmacol. 2001, 62, 207-212.
     
  128. McLeod, H. L.; Sludden, J.; Murray, G. I.; Keenan, R. A.; Davidson, A.; Park, K.; Koruth, M.; Cassidy, J. Characterization of dihydropyrimidine dehydrogenase in human colorectal tumors. Br. J. Cancer 1998, 77, 461-465.
     
  129. Mechetner, E.; Kyshtoobayeva, A.; Zonis, S.; Kim, H.; Stroup, R.; Garcia, R.; Parker, R. J.; Fruehauf, J. P. Levels of multidrug resistance (MDR1) P glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin. Cancer Res. 1998, 4, 389-398.
     
  130. Medhora, M.; Dhanasekaran, A.; Gruenloh, S. K.; Dunn, L. K.; Gabrilovich, M.; Falck, J. R.; Harder, D. R.; Jacobs, E. R.; Pratt, P. F. Emerging mechanisms for growth and protection of the vasculature by cytochrome P450-derived products of arachidonic acid and other eicosanoids. Prostaglandins Other Lipid Mediat. 2007, 82, 19-29.
     
  131. Michael, M.; Doherty, M. M. Tumoral drug metabolism: overview and its implications for cancer therapy. J. Clin. Oncol. 2005, 23, 205-229.
     
  132. Mignogna, C.; Staibano, S.; Altieri, V.; De Rosa, G.; Pannone, G.; Santoro, A.; Zamparese, R.; D'Armiento, M.; Rocchetti, R.; Mezza, E.; Nasti, M.; Strazzullo, V.; Montanaro, V.; Mascolo, M.; Bufo, P. Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis. BMC Cancer 2006, 6, 293-303.
     
  133. Miyoshi, Y.; Ando, A.; Takamura, Y.; Taguchi, T.; Tamaki, Y.; Noguchi, S. Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues. Int. J. Cancer 2002, 97, 129-132.
     
  134. Mohammed, K.; Shervington, A. Can CYP1A1 siRNA be an effective treatment for lung cancer? Cell. Mol Biol. Lett. 2008, 13, 240-249.
     
  135. Moon, K.; Sonnenburg, J.; Salyers, A. A. Unexpected effect of a Bacteroides conjugative transposon, CTnDOT, on chromosomal gene expression in its bacterial host. Mol. Microbiol. 2007, 64, 1562-1571.
     
  136. Morrow, C. S.; Diah, S.; Smitherman, P. K.; Schneider, E.; Townsend, A. J. Multidrug resistance protein and glutathione S-transferase P1-1 act in synergy to confer protection from 4-nitroquinoline 1-oxide toxicity. Carcinogenesis 1998, 19, 109-115.
     
  137. Morrow, C. S.; Smitherman, P. K.; Diah, S. K.; Schneider, E.; Townsend, A. J. Coordinated action of glutathione S-transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification. Mechanism of GST A1-1- and MRP1-associated resistance to chlorambucil in MCF7 breast carcinoma cells. J. Biol. Chem. 1998, 273, 20114-20120.
     
  138. Müller, J.; Lips, K. S.; Metzner, L.; Neubert, R. H.; Koepsell, H.; Brandsch M. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem. Pharmacol. 2005, 70, 1851-1860.
     
  139. Muller, M.; Meijer, C.; Zaman, G. J.; Borst, P.; Scheper, R. J.; Mulder, N. H.; de Vries, E. G.; Jansen, P. L. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 13033-13037.
     
  140. Murray, G. I.; Taylor, M. C.; McFadyen, M. C.; McKay, J. A.; Greenlee, W. F.; Burke, M. D.; Melvin, W. T. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res. 1997, 57, 3026-3031.
     
  141. Mussi, M. A.; Limansky, A. S.; Viale, A. M. Acquisition of resistance to carbapenems in multidrug-resistant clinical strains of Acinetobacter baumannii: natural insertional inactivation of a gene encoding a member of a novel family of beta-barrel outer membrane proteins. Antimicrob. Agents Chemother. 2005, 49, 1432-1440.
     
  142. Nagasawa, K.; Natazuka, T.; Chihara, K.; Kitazawa, F.; Tsumura, A.; Takara, K.; Nomiyama, M.; Ohnishi, N.; Yokoyama ,T. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of pirarubicin in HL60 and pirarubicin-resistant HL60 cells. Cancer Chemother. Pharmacol. 1996, 37, 297-304.
     
  143. Nakumura, T.; Sakaeda, T.; Ohmoto, N.; Moriya, Y.; Komoto, C.; Shirakawa, T.; Gotoh, A.; Matsuo, M.; Okmura, K. Gene expression profiles of ABC transporters and cytochrome P450 3A in Caco-2 and human colorectal cancer cell lines. Pharm. Res. 2003, 20, 324-347.
     
  144. Nassar, AE and Talaat, RE Strategies for dealing with metabolite elucidation in drug discovery and development. Drug Discov Today, 2004; 9(7): 317-327
     
  145. Nawa, A.; Tanino, T.; Luo, C.; Iwaki, M.; Kajiyama, H.; Shibata, K.; Yamamoto, E.; Ino, K.; Nishiyama, Y.; Kikkawa, F. Gene directed enzyme prodrug therapy for ovarian cancer: could GDEPT become a promising treatment against ovarian cancer? Anti-Cancer Agents Med. Chem. 2008, 8, 232-239.
     
  146. Nguyen, T. A.; Tychopoulos, M.; Bichat, F.; Zimmermann, C.; Flinois, J. P.; Diry, M.; Ahlberg, E.; Delaforge, M.; Corcos, L.; Beaune, P.; Dansette, P.; André, F.; de Waziers, I. Improvement of cyclophosphamide activation by CYP2B6 mutants: from in silico to ex vivo. Mol. Pharmacol. 2008, 73, 1122-1133.
     
  147. Nimmanapalli, R.; O'Bryan, E.; Huang, M.; Bali, P.; Burnette, P. K.; Loughran, T.; Tepperberg, J.; Jove, R.; Bhalla, K. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 2002, 60, 5761-5769.
     
  148. Niwa, T.; Shiraga, T.; Ishii, I.; Kagayama, A.; Takagi, A. Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol. Pharm. Bull. 2005, 28, 1711-1716.
     
  149. Nobili, S.; Landini, I.; Giglioni, B.; Mini, E. Pharmacological strategies for overcoming multidrug resistance. Curr. Drug Targets. 2006, 7, 861-879.
     
  150. Okabe, M.; Unno, M.; Harigae, H.; Kaku, M.; Okitsu, Y.; Sasaki, T.; Mizoi, T.; Shiiba, K.; Takanaga, H.; Terasaki, T.; Matsuno, S.; Sasaki, I.; Ito, S.; Abe, T. Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem. Biophys. Res. Commun. 2005, 333, 754-762.
     
  151. Olinga, P.; Elferink, M. G.; Draaisma, A. L.; Merema, M. T.; Castell, J. V. Perez, G.; Groothuis, G. M. Coordinated induction of drug transporters and phase I and II metabolism in human liver slices. Eur. J. Pharm. Sci. 2008, 33, 380-389.
     
  152. Oscarson, M.; Zanger, U. M.; Rifki, O. F.; Klein, K.; Eichelbaum, M.; Meyer, U. A. Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin. Pharmacol. Ther. 2006, 80, 440-456.
     
  153. Oyama, T.; Kagawa, N.; Kunugita, N.; Kitagawa, K.; Ogawa, M.; Yamaguchi, T.; Suzuki, R.; Kinaga, T.; Yashima, Y.; Ozaki, S.; Isse, T.; Kim, Y. D.; Kim, H.; Kawamoto, T. Expression of cytochrome P450 in tumor tissues and its association with cancer development. Front. Biosci. 2004, 9, 1967-1976.
     
  154. Parikh, S.; Gagne, P.; Miller, V.; Crespi, C.; Thummel, K.; Patten, C. CYP2J2 and CYP4F12 are active for the metabolism of non-sedating antihistamines: terfenadine and astemizole. Drug Metab. Rev. 2003, 35, 190-191.
     
  155. Paul, C.; Liliemark, J.; Tidefelt, U.; Gahrton, G.; Peterson, C. Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia. Ther. Drug Monit. 1989, 11, 140-148.
     
  156. Paumi, C. M.; Ledford, B. G.; Smitherman, P. K.; Townsend, A. J.; Morrow, C. S. Role of multidrug resistance protein 1 (MRP1) and glutathione S-transferase A1-1 in alkylating agent resistance. Kinetics of glutathione conjugate formation and efflux govern differential cellular sensitivity to chlorambucil versus melphalan toxicity. J. Biol. Chem. 2001, 276, 7952-7956.
     
  157. Peklak-Scott, C.; Townsend, A. J.; Morrow, C. S. Dynamics of glutathione conjugation and conjugate efflux in detoxification of the carcinogen, 4-nitroquinoline 1-oxide: contributions of glutathione, glutathione S-transferase, and MRP1. Biochemistry 2005, 44, 4426-4433.
     
  158. Pérez-Tomás, R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr. Med. Chem. 2006, 13, 1859-1876.
     
  159. Petros, W. P.; Hopkins, P. J.; Spruill, S.; Broadwater, G.; Vredenburgh, J. J.; Colvin, O. M.; Peters, W. P.; Jones, R. B.; Hall, J.; Marks, J. R. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J. Clin. Oncol. 2005, 23, 6117-6125.
     
  160. Piddock, L. J. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin. Microbiol. Rev. 2006, 19, 382-402.
     
  161. Pinnix CC, Lee JT, Liu ZJ, McDaid R, Balint K, Beverly LJ, Brafford PA, Xiao M, Himes B, Zabierowski SE, Yashiro-Ohtani Y, Nathanson KL, Bengston A, Pollock PM, Weeraratna AT, Nickoloff BJ, Pear WS, Capobianco AJ, Herlyn M. Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res. 2009;69:5312-5320
     
  162. Poole, K. Efflux pumps as antimicrobial resistance mechanisms. Ann. Med. 2007, 39, 162-176.
     
  163. Pumbwe, L.; Wareham, D. W.; Aduse-Opoku, J.; Brazier, J. S.; Wexler, H. M. Genetic analysis of mechanisms of multidrug resistance in a clinical isolate of Bacteroides fragilis. Clin. Microbiol. Infect. 2007, 13, 183-189.
     
  164. Rieger, M. A.; Ebner, R.; Bell, D. R.; Kiessling, A.; Rohayem, J.; Schmitz, M.; Temme, A.; Rieber, E. P.; Weigle, B. Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma. Cancer Res. 2004, 64, 2357-2364.
     
  165. Robert, J.; Morvan, V. L.; Smith, D.; Pourquier, P.; Bonnet, J. Predicting drug response and toxicity based on gene polymorphisms. Crit. Rev. Oncol. Hematol. 2005, 54, 171-196.
     
  166. Rochat B. Evaluation of recombinant cytochromes P450 activity in metabolic pathways. Drug Metab Dispos. 2003;31:145-6
     
  167. Rochat B. Role of Influx and Efflux Systems and Xenobiotic Metabolizing Enzymes in the Intratumoral Disposition of Anti-Cancer Agents. Curr Cancer Drug Targets. 2009;9:652-74.
     
  168. Rochat, B. Role of cytochrome p450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, Paclitaxel and imatinib metabolism. Clin. Pharmacokinet. 2005, 44, 349-366.
     
  169. Rochat, B.; Fayet, A.; Widmer, N.; Lahrichi, S. L.; Pesse, B.; Décosterd, L. A.; Biollaz, J. Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry. J. Mass Spectrom. 2008, 43, 43736-43752.
     
  170. Rochat, B.; Morsman, J. M.; Murray, G. I.; Figg, W. D.; McLeod, H. L. Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J. Pharmacol. Exp. Ther. 2001, 296, 537-541.
     
  171. Rochat, B.; Zoete, V.; Grosdidier, A.; von Grünigen, S.; Marull, M.; Michielin, O. In Vitro Biotransformation of Imatinib by the Tumor Expressed CYP1A1 and CYP1B1. Biopharm. Drug Dispos. 2008, 29,103-118.
     
  172. Roman, R. J. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 2002, 82, 131-185.
     
  173. Rooseboom, M.; Commandeur, J. N.; Vermeulen, N. P. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev. 2004, 56, 53-102.
     
  174. Rottenberg, S.; Nygren, A. O.; Pajic, M.; van Leeuwen, F. W.; van der Heijden, I.; van de Wetering, K.; Liu, X.; de Visser, K. E.; Gilhuijs, K. G.; van Tellingen, O.; Schouten, J. P.; Jonkers, J.; Borst, P. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 12117-12122.
     
  175. S. Rottenberg, A. Kersbergen, E. van der Burg, N. de Water, A. Nygren, M. Pajic, F. van Leeuwen, O. van Tellingen, A. Schinkel, J. Jonkers, P. Borst. Abcb1a, Abcb1b and Abcg2 induce chemotherapy resistance in a realistic mouse model for human hereditary breast cancer. Poster presentation at the 5th International Research Conference on Biomedical Transporters 2007
     
  176. Roy, P.; Waxman, D. J. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer. Toxicol. In Vitro. 2006, 20, 176-186.
     
  177. Salonga, D.; Danenberg, K. D.; Johnson, M.; Metzger, R.; Groshen, S.; Tsao-Wei, D. D.; Lenz, H. J.; Leichman, C. G.; Leichman, L.; Diasio, R. B.; Danenberg, P. V. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 2000, 6, 1322-1327.
     
  178. Sasabe, H.; Terasaki, T.; Tsuji, A.; Sugiyama, Y. Carrier-mediated hepatic uptake of quinolone antibiotics in the rat. J. Pharmacol. Exp. Ther. 1997, 282, 162-171.
     
  179. Scappini, B.; Gatto, S.; Onida, F.; Ricci, C.; Divoky, V.; Wierda, W. G.; Andreeff, M.; Dong, L.; Hayes, K.; Verstovsek, S.; Kantarjian, H. M.; Beran, M. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein. Cancer 2004, 100, 1459-1471.
     
  180. Schrenk, D.; Gant, T. W.; Michalke, A.; Orzechowski, A.; Silverman, J. A.; Battula, N.; Thorgeirsson, S. S. Metabolic activation of 2-acetylaminofluorene is required for induction of multidrug resistance gene expression in rat liver cells. Carcinogenesis. 1994, 15, 2541-2546.
     
  181. Schulz, W.A.; Retrotransposons. J. Biomed. Biotechnol. 2006, 2006, 83672-83681.
     
  182. Scripture, C. D.; Sparreboom, A.; Figg, W. D. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol. 2005, 6, 780-789.
     
  183. Ségui, B.; Andrieu-Abadie, N.; Jaffrézou, J. P.; Benoist, H.; Levade, T. Sphingolipids as modulators of cancer cell death: potential therapeutic targets. Biochim. Biophys. Acta. 2006, 1758, 2104-2120.
     
  184. Sharma, M.; Shubert, D.E.; Sharma, M.; Lewis, J.; McGarrigle, B. P.; Bofinger, D. P.; Olson, J. R. Biotransformation of tamoxifen in a human endometrial explant culture model. Chem. Biol. Interact. 2003, 146, 237-249.
     
  185. Shervington, A.; Mohammed, K.; Patel, R.; Lea, R. Identification of a novel co-transcription of P450/1A1 with telomerase in A549. Gene 2007, 388, 110-116.
     
  186. Shiraga, T.; Tozuka, Z.; Ishimura, R.; Kawamura, A.; Kagayama, A. Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes. Biol. Pharm. Bull. 2005, 28, 124-129.
     
  187. Sissung, T. M.; Danesi, R.; Price, D. K.; Steinberg, S. M.; de Wit, R.; Zahid, M.; Gaikwad, N.; Cavalieri, E.; Dahut, W. L.; Sackett, D. L.; Figg, W. D.; Sparreboom, A. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol. Cancer Ther. 2008, 7, 19-26.
     
  188. Sissung, T. M.; Gardner, E. R.; Gao, R.; Figg, W. D. Pharmacogenetics of membrane transporters: a review of current approaches. Methods Mol. Biol. 2008, 448, 41-62.
     
  189. Sjöblom, T.; Jones, S.; Wood, L. D.; Parsons, D. W.; Lin, J.; Barber, T. D.; Mandelker, D.; Leary, R.J.; Ptak, J.; Silliman, N.; Szabo, S.; Buckhaults, P.; Farrell, C.; Meeh, P.; Markowitz, S.D.; Willis, J.; Dawson, D.; Willson, J. K.; Gazdar, A. F.; Hartigan, J.; Wu, L.; Liu, C.; Parmigiani, G.; Park, B. H.; Bachman, K. E.; Papadopoulos, N.; Vogelstein, B.; Kinzler, K. W.; Velculescu, V. E. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314, 268-274.
     
  190. Smitherman, P. K.; Townsend, A. J.; Kute, T. E.; Morrow, C. S. Role of multidrug resistance protein 2 (MRP2, ABCC2) in alkylating agent detoxification: MRP2 potentiates glutathione S-transferase A1-1-mediated resistance to chlorambucil cytotoxicity. J. Pharmacol. Exp. Ther. 2004, 308, 260-267.
     
  191. Sparreboom, A.; Danesi, R.; Ando, Y.; Chan, J.; Figg, W. D. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist. Updat. 2003, 6, 71-84.
     
  192. Stark, K.; Guengerich, F. P. Characterization of orphan human cytochromes P450. Drug. Metab. Rev. 2007, 39, 627-637.
     
  193. Sun, D.; Sharma, A. K.; Dellinger, R. W.; Blevins-Primeau, A. S.; Balliet, R. M.; Chen, G.; Boyiri, T.; Amin, S.; Lazarus, P. Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab. Dispos. 2007, 35, 2006-2014.
     
  194. Synold, T. W.; Dussault, I.; Forman, B. M. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat. Med. 2001, 7, 584-590.
     
  195. Szakács, G.; Annereau, J. P.; Lababidi, S.; Shankavaram, U.; Arciello, A.; Bussey, K. J.; Reinhold, W.; Guo, Y.; Kruh, G. D.; Reimers, M.; Weinstein, J. N.; Gottesman, M.M. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell. 2004, 6, 129-137.
     
  196. Tahara, H.; Kusuhara, H.; Endou, H.; Koepsell, H.; Imaoka, T.; Fuse, E.; Sugiyama, Y. A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J. Pharmacol. Exp. Ther. 2005, 315, 337-345.
     
  197. Takeda, S.; Ishii, Y.; Iwanaga, M.; Mackenzie, P. I.; Nagata, K.; Yamazoe, Y.; Oguri, K.; Yamada, H. Modulation of UDP-glucuronosyltransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4. Mol. Pharmacol. 2005, 67, 665-672.
     
  198. Thomas, J.; Wang, L.; Clark, R. E.; Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004, 104, 3739-3745.
     
  199. Tidefelt, U.; Liliemark, J.; Gruber, A.; Liliemark, E.; Sundman-Engberg, B.; Juliusson, G.; Stenke, L.; Elmhorn-Rosenborg, A.; Möllgård, L.; Lehman, S.; Xu, D.; Covelli, A.; Gustavsson, B.; Paul, C. P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. J. Clin. Oncol. 2000, 18, 1837-1844.
     
  200. Tokizane, T.; Shiina, H.; Igawa, M.; Enokida, H.; Urakami, S.; Kawakami, T.; Ogishima, T.; Okino, S. T.; Li, L. C.; Tanaka, Y.; Nonomura, N.; Okuyama, A.; Dahiya, R. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin. Cancer Res. 2005, 11, 5793-5801.
     
  201. Tolle-Sander, S.; Rautio, J.; Wring, S.; Polli, J. W.; Polli, J. E. Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. Pharm. Res. 2003, 20, 757-64.
     
  202. Tozuka, Z, Kaneko, H, Shiraga, T, et al. Strategy for structural elucidation of drugs and drug metabolites using (MS)n fragmentation in an electrospray ion trap. J Mass Spectrom, 2003; 38(8):793-808
     
  203. Tsuchiya, Y.; Nakajima, M.; Takagi, S.; Taniya, T.; Yokoi T. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res. 2006, 66, 9090-9098.
     
  204. Veenstra DL, Higashi MK, Phillips KA. Assessing the cost-effectiveness of pharmacogenomics. AAPS Pharm Sci 2000; 2: E29
     
  205. Voso, M.T.; D'Alo', F.; Gumiero, D.; Guidi, F.; Hohaus, S.; Leone, G. The CYP1A1*2a allele is an independent prognostic factor for acute myeloid leukemia. Haematologica 2005, 90, 982-984.
     
  206. Wacher, V. J.; Wu, C. Y.; Benet, L. Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 1995, 13, 129-134.
     
  207. Wang, L.; Giannoudis, A.; Lane, S.; Williamson, P.; Pirmohamed, M.; Clark, R. E. Expression of the Uptake Drug Transporter hOCT1 is an Important Clinical Determinant of the Response to Imatinib in Chronic Myeloid Leukemia. Clin. Pharmacol. Ther. 2008, 83, 258-264.
     
  208. Wang, M. Z.; Wu, J. Q.; Bridges, A. S.; Zeldin, D. C.; Kornbluth, S.; Tidwell, R. R.; Hall, J. E.; Paine, M. F. Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine. Drug Metab. Dispos. 2007, 35, 2067-2075.
     
  209. White, D. L.; Saunders, V. A.; Dang, P.; Engler, J.; Zannettino, A. C.; Cambareri, A. C.; Quinn, S. R.; Manley, P. W.; Hughes, T. P. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006, 108, 697-4.
     
  210. Widmer, N.; Colombo, S.; Buclin, T.; Decosterd, L. A. Functional consequence of MDR1 expression on imatinib intracellular concentrations. Blood 2003, 102, 1142.
     
  211. Wu, S.; Moomaw, C. R.; Tomer, K. B.; Falck, J. R.; Zeldin, D. C. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J. Biol. Chem. 1996, 271, 3460-3468.
     
  212. Xu, C.; Li, C. Y.; Kong, A. N. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res. 2005, 28, 249-268.
     
  213. Xu, G.; McLeod, H. L. Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res. 2001, 7, 3314-3324.
     
  214. Yabuki, N.; Sakata, K.; Yamasaki, T.; Terashima, H.; Mio, T.; Miyazaki, Y.; Fujii, T.; Kitada, K. Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance. Cancer Genet. Cytogenet. 2007, 173, 1-9.
     
  215. Yakkundi, A.; McErlane, V.; Murray, M.; McCarthy, H.O.; Ward, C.; Hughes, C.M.; Patterson, L.H.; Hirst, D.G.; McKeown, S.R.; Robson, T. Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N. Cancer Gene Ther. 2006, 13, 598-605.
     
  216. Yang, S.; Lin, L.; Chen, J. X.; Lee, C. R.; Seubert, J. M.; Wang, Y.; Wang, H.; Chao, Z. R.; Tao, D. D.; Gong, J. P.; Lu, Z. Y.; Wang, D. W.; Zeldin, D. C. Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-alpha via MAPK and PI3K/Akt signaling pathways. Am. J. Physiol. Heart Circ. Physiol. 2007, 293, 142-151.
     
  217. Yu L.J.; Matias, J.; Scudiero, D. A.; Hite, K. M.; Monks, A.; Sausville, E. A; Waxman, D. J. P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab. Dispos. 2001, 29, 304-312.
     
  218. Zeldin, D. C. Epoxygenase pathways of arachidonic acid metabolism. J. Biol. Chem. 2001, 276, 36059-36062
     
  219. Zeng, H.; Liu, G.; Rea, P. A.; Kruh, G. D. Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res. 2000, 60, 4779-4784.
     
  220. Zhang, J.; Tian, Q.; Zhu, Y. Z.; Xu, A. L.; Zhou, S. F. Reversal of resistance to oxazaphosphorines. Curr. Cancer Drug Targets. 2006, 6, 385-407.
     
  221. Zhang, W.; Shannon, W. D.; Duncan, J.; Scheffer, G. L.; Scheper, R. J.; McLeod, H. L. Expression of drug pathway proteins is independent of tumour type. J. Pathol. 2006, 209, 213-219.
     
  222. Zhou, F.; Illsley, N. P.; You, G. Functional characterization of a human organic anion transporter hOAT4 in placental BeWo cells. Eur. J. Pharm. Sci. 2006, 27, 518-523.


Search:
 in this site:
   
   
   
 Rechercher

CH-1015 Lausanne  - Switzerland  -  Phone +41 21 314 41 58  -  Fax  +41 21 314 41 65